Press review

 - 

AstraZeneca shareholders revolt over CEO pay

Country : Japan, U.S., UK

Keywords :
LONDON, 25 May (APM) - AstraZeneca’s shareholder revolt over executive pay was widely picked up at the weekend.
The Guardian, the Financial Times and The Times all picked up the news that more than 37% of shareholders voted against or abstained at the company’s annual shareholder meeting in London on Friday.
The rebellion opposed a £9.4 million pay package for chief executive Pascal Soriot, even though this was a drop from £14.3m a year earlier.

May backs UK to be leader in AI in healthcare

UK prime minister Theresa May backed artificial intelligence to diagnose several types of cancer in a speech on Monday, said that day’s FT. (APMHE 58170)
The paper said May set targets for a “whole new industry around AI-in-healthcare” in the UK, centred on Edinburgh, Oxford and Leeds.

Takeda CEO says Shire acquisition will make company more resilient to pricing pressures

Takeda’s chief executive Christophe Weber said the acquisition of Shire will strengthen the company’s focus on innovative medicines and make it more “resilient” to pricing pressures in the U.S., the FT said on Monday.
Weber discussed plans by U.S. president Donald Trump to lower drug prices, saying he was convinced that the U.S. would remain “a pro-innovation market”. However, he added: “It will be a more demanding market, like many other countries — like Japan, as an example — where price and reimbursement will be more stringent.”

Pfizer under pressure to resolve shortages of EpiPen

Mylan, the company behind the EpiPen allergy injector, is pressing its manufacturing partner Pfizer to do more to tackle shortages of the life-saving medicine in a sign of its growing frustration with the big pharma company, the FT reported on Thursday.
Although Mylan owns the rights to the EpiPen — which can stave off deadly anaphylactic shock — it subcontracts manufacturing of the auto-injector to Meridian Medical, a division of Pfizer.
However, Pfizer has struggled to meet demand for the allergy injector, resulting in some patients having difficulties finding the product in their local pharmacies. The U.S. Food and Drug Administration put the medicine on its official shortages list earlier this month.

Pfizer agrees to pay nearly $24 million to settle kickback claims

Pfizer has agreed to pay almost $24 million to settle claims it paid kickbacks to Medicare patients who used its medicines, the U.S. Department of Jusice said, the FT reported on Thursday.
The U.S. pharma allegedly used third party foundations to route payments to patients using three Pfizer drugs, according to the DoJ.
Patients using the U.S. Medicare system have some of the cost of treatment paid for by the government, but also have to make a partial 'co-pay' payment.
tm/nh/clg

[TM9P92LPM]

TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT

Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to our last stories

Request a trial to assess coverage that includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.

REQUEST

an initial 10 day temporary access of APM Health Europe.